Logotype for Cresco Labs Inc

Cresco Labs (CL) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Cresco Labs Inc

Q1 2026 earnings summary

11 May, 2026

Executive summary

  • Q1 2026 revenue reached $151.3 million, with $77 million in adjusted gross profit, $33 million in Adjusted EBITDA (21.7% margin), and a net loss of $17 million, reflecting efficiency gains and a solid baseline for growth initiatives.

  • Maintained leading wholesale market share in multiple billion-dollar cannabis markets, supported by a strong brand portfolio and 77 operating retail locations as of March 31, 2026.

  • Strategic expansion included entering a management agreement for nine new dispensaries in Pennsylvania and opening two new stores in Ohio, increasing the total footprint and positioning for future adult use opportunities.

  • Secured a conditional Texas Compassionate Use Program license and began revenue generation in Kentucky, with Kentucky shifting from investment to revenue generation after first harvest in April.

  • Federal rescheduling of medical cannabis to Schedule III is expected to benefit the business, particularly through the removal of 280E tax constraints.

Financial highlights

  • Q1 2026 net revenue was $151.3 million, with adjusted gross profit of $76.7 million (50.7% margin) and adjusted EBITDA of $32.9 million (21.7% margin).

  • Net loss for Q1 2026 was $17 million.

  • Adjusted SG&A was $51 million (33.7% of revenue), reflecting investments in growth initiatives and offset by productivity gains.

  • Cash, cash equivalents, and restricted cash totaled $67 million as of March 31, 2026.

  • Free cash flow for Q1 2026 was negative $13.2 million.

Outlook and guidance

  • Q2 revenue expected to increase approximately 10% sequentially, driven by new dispensaries and market stabilization.

  • Gross margins anticipated to remain between 48%-50%, with Adjusted EBITDA margins near 21%.

  • SG&A expected to rise modestly due to new store openings and M&A activity.

  • Management expects to benefit from the reclassification of medical marijuana to Schedule III, which should eliminate Section 280E tax impacts on medical operations.

  • Growth initiatives in Kentucky and Texas expected to scale over time, with Kentucky's contributions modest in 2026 but growing into 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more